Search Results
Your search for The A,The A matches 32311 pages
Showing 1851 - 1900Esophageal Squamous Cell Cancer: Overall Survival Improved With Tiragolumab and Atezolizumab Plus Chemotherapy
For patients with treatment-naive, locally advanced or metastatic esophageal squamous cell carcinoma, the addition of two checkpoint inhibitors to chemotherapy significantly improved not only progression-free survival but also overall survival, in the randomized, phase III SKYSCRAPER-08 trial...
Novel MDM2 Inhibitor for Salivary Gland Cancers
A novel MDM2 inhibitor, APG-115 (alrizomadlin), has demonstrated antitumor activity and good tolerability in patients with progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented by Swiecicki et al at the 2024 Multidisciplinary Head and Neck Cancers Symposium ...
Primary Tumor Resection Before Chemotherapy in Patients With Colon Cancer and Unresectable Metastases
In a pooled analysis reported in the Journal of Clinical Oncology, Rahbari et al found that primary tumor resection before chemotherapy did not extend survival compared with upfront chemotherapy in patients with colon cancer and unresectable metastases. Study Details The study involved data from...
Five New Cancer Grand Challenges Teams Named in Global Effort to Resolve Hurdles in Cancer Research
The Cancer Grand Challenges initiative announced it has selected five new global teams that will each receive up to $25 million in funding over the course of 5 years to address four major challenges faced by cancer research. Background In March 2023, the initiative unveiled nine new challenges to...
Inherited Genetic Factors May Influence Risk of Subsequent Cancer Diagnoses in Childhood Cancer Survivors
Investigators have found that common inherited genetic factors capable of predicting cancer risk in the general population may also help to predict childhood cancer survivors who may be at elevated risk of new cancers later in life, according to a recent study published by Gibson et al in Nature...
FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma
On March 7, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the small-molecule BTK inhibitor zanubrutinib (Brukinsa) in combination with the anti-CD20 monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of ...
FDA Approves Nivolumab in Combination With Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma
On March 6, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. CheckMate 901 Efficacy was evaluated in CheckMate ...
Topical Diclofenac to Prevent Capecitabine-Associated Hand-Foot Syndrome
In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast or gastrointestinal cancer who were ...
Patients With Early-Stage HR-Positive Breast Cancer May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
Newly published study results revealed that use of the Breast Cancer Index (BCI) test led to physicians changing their long-term antiestrogen treatment recommendations for 40% of patients with early-stage hormone receptor–positive breast cancer. The results, which suggest that many women may be...
Physician Attitudes Toward 2020 ACS Cervical Cancer Screening Guidelines
Investigators have uncovered that despite low adoption rates of the 2020 American Cancer Society (ACS) cervical cancer screening guidelines among physicians, a majority of them expressed willingness to utilize the recommendations under certain circumstances, according to a recent study published by ...
Finding New Therapeutic Targets for Male Breast Cancer
Researchers have uncovered distinct alterations in the tumor genome of male patients with breast cancer that may suggest potential therapeutic targets, according to a recent study published by Assaad et al in Modern Pathology. Background Breast cancer in male patients represents less than 1% of all ...
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
On March 6, the U.S. Food and Drug Administration (FDA) approved the CD22-targeted antibody-drug conjugate inotuzumab ozogamicin (Besponsa) for pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Study WI203581...
Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report
Dan P. Zandberg, MD, of UPMC Hillman Cancer Center, discusses study results showing that, although efficacy was low with both nivolumab plus ipilimumab and nivolumab plus relatlimab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC), selected patients...
Samuel Regan, MD, and Benjamin Rosen, PhD, on De-escalating Radiotherapy for HPV-Related Oropharyngeal Cancer
Samuel Regan, MD, and Benjamin Rosen, PhD, both of the University of Michigan, discuss results from a phase II trial showing the possibility of de-escalating chemoradiation treatment for patients with HPV-related oropharyngeal cancer, based on an FDG-PET imaging biomarker. The data suggest that...
Eleni M. Rettig, MD, on HPV-Related Oropharyngeal Cancers: Early Detection and Disease Surveillance
Eleni M. Rettig, MD, of Brigham and Women’s Hospital, discusses the promising but thus far limited data on using circulating tumor HPV DNA for early detection of HPV-related oropharyngeal cancers, which highlights the importance of developing a reliable biomarker (Poster Abstract 177).
Factors Associated With Myeloid Neoplasms Following CAR T-Cell Therapy
In an analysis reported in a research letter in JAMA Oncology, Gurney et al identified factors associated with an increased risk of myeloid neoplasms after chimeric antigen receptor (CAR) T-cell therapy. Study Details Investigators identified adults who received CAR T-cell therapy between June 2016 ...
Evan M. Graboyes, MD, MPH, on Addressing Body Image Distress: Critical Care for Head and Neck Cancer Survivors
Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses body image distress, a source of significant morbidity among head and neck cancer survivors. He recommends strategies to identify this side effect, the evidence for how best to treat, and best practices to help...
Novel CD123-Targeting Antibody-Drug Conjugate in Relapsed or Refractory AML
In a phase I/II study reported in The Lancet Oncology, Naval Daver, MD, and colleagues found that pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, showed activity in patients with CD123-positive relapsed or refractory acute myeloid leukemia (AML). Study Details...
Low-Risk Cervical Cancer: Pelvic Recurrence With Simple vs Radical Hysterectomy
As reported by Marie Plante, MD, and colleagues in The New England Journal of Medicine, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in terms of pelvic recurrence in women with low-risk cervical cancer. Simple hysterectomy was associated with a reduced...
Medical Debt May Be Associated With Poorer Health Status and Survival Outcomes at U.S. County Level
Medical debt is associated with worse health status, more premature deaths, and higher mortality rates in the United States, according to a recent cross-sectional study published by Han et al in JAMA Network Open. Background“Patients are increasingly burdened by high out-of-pocket costs for health...
Could Smoking-Related DNA Changes Reflect Differential Lung Cancer Risks by Race and Ethnicity?
Investigators may have uncovered differential associations between smoking and DNA methylation across various racial and ethnic groups, according to a recent study published by Huang et al in the American Journal of Human Genetics. The findings could lead to the development of new strategies to...
Endocrine-Resistant HR-Positive/HER2-Negative Metastatic Breast Cancer
This is Part 3 of Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Kevin Kalinsky, Manali Bhave, and Ruth O’Regan discuss the treatment of...
HR-Positive/HER2-Negative Metastatic Breast Cancer With PIK3CA Mutation
This is Part 2 of Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Kevin Kalinsky, Manali Bhave, and Ruth O’Regan discuss the treatment of...
Second-Line Treatment of HR-Positive/HER2-Negative ESR1-Mutated Metastatic Breast Cancer
This is Part 1 of Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Kevin Kalinsky, Manali Bhave, and Ruth O’Regan discuss the treatment of...
HPV-Associated Oropharyngeal Cancer: Adjuvant Treatment Deintensification
Postoperative adjuvant therapy—both chemoradiotherapy and radiotherapy alone—for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma may be safely de-escalated, according to results presented by Thorstad et al at the 2024 Multidisciplinary Head and Neck Cancers Symposium...
Variations in Use of Chemotherapy in Patients With Newly Diagnosed Common Cancers
In an International Cancer Benchmarking Partnership study reported in The Lancet Oncology, McPhail et al found wide interjurisdictional variation in chemotherapy use among patients with newly diagnosed common cancers in Norway, the United Kingdom, Canada, and Australia. Study Details The study...
HPV Vaccination Among Young Adults Prior to and During the COVID-19 Pandemic
In a study reported in JAMA Network Open, Sonawane et al found that no increase in human papillomavirus (HPV) vaccination rates among young adults was observed during the COVID-19 pandemic in the United States, contrary to the increased rates observed prior to the pandemic. Study Details The study...
Can Dual HER2 Blockade Treat More Than Just Breast or Gastric Cancer?
The established dual HER2 blockade of pertuzumab and trastuzumab may be an effective treatment for patients with several types of HER2-amplified cancers, according to a study published by Connolly et al in Clinical Cancer Research. Background HER2 receptors control how cells grow and divide. The...
Social Determinants of Health Potentially Responsible for Low Breast Cancer Screening Rates
Investigators may have uncovered the social determinants of health hindering breast cancer screening in the United States, according to a recent systematic review published by Jhumkhawala et al in Frontiers in Public Health. Background Health disparities have consistently been associated with...
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and Other Cancers
The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for...
Lenvatinib Plus Pembrolizumab Fails to Improve Overall Survival in Recurrent or Metastatic Head and Neck Cancer
Adding the multikinase inhibitor lenvatinib to the PD-1 inhibitor pembrolizumab as initial therapy for recurrent or metastatic head and neck squamous cell carcinoma improved response rates and progression-free survival but did not lead to an overall survival advantage over pembrolizumab...
Can HPV ctDNA Guide the Adjuvant Treatment of Oropharyngeal Cancer?
Although liquid biopsies are now helping determine the need for adjuvant therapy in a number of malignancies, they have yet to prove useful in the setting of oropharyngeal carcinoma, according to a prospective pilot study presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium that...
Racial/Ethnic Differences in Treatment Outcomes Among Patients With Triple-Negative Breast Cancer
In a study reported in the Journal of Clinical Oncology, Woriax et al identified racial/ethnic differences in pathologic complete response rates and overall survival among women with triple-negative breast cancer who received neoadjuvant chemotherapy. Study Details The study involved data from the...
FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion–Mutated NSCLC
On March 1, the FDA approved the monoclonal bispecific anti–EGFR-MET antibody amivantamab-vmjw (Rybrevant) in combination with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test....
Disparities in Treatment Outcomes Among Non-Hispanic Black Patients With Locally Advanced Rectal Cancer
Non-Hispanic Black patients with locally advanced rectal cancer may experience poorer treatment outcomes independent of the sociodemographic, clinical, and pathologic factors that often influence racial and ethnic disparities in this patient population, according to a recent study published by...
Impact of Behavioral Health Disorders on Cancer Surgery Outcomes
Investigators may have uncovered new insights into the relationship between behavioral health disorders and cancer surgery outcomes, according to a recent study published by Katayama et al in the Journal of the American College of Surgeons. The findings clarified the need for behavioral health...
Circulating Leukocyte Subsets After Breast Cancer Diagnosis and Treatment
In an analysis reported in JAMA Network Open, Jacob K. Kresovich, PhD, and colleagues identified differences in circulating leukocyte subsets between women who were diagnosed and treated for breast cancer vs those not diagnosed with breast cancer. As stated by the investigators: “Changes in...
Advanced Multiple Myeloma: Prediction Model for Outcomes After BCMA-Directed CAR T-Cell Therapy
As reported in the Journal of Clinical Oncology, Gagelmann et al have developed a predictive model (Myeloma CAR-T Relapse [MyCARe] model) for outcomes after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory multiple...
Nasopharyngeal Carcinoma: Radiotherapy vs Chemoradiotherapy After Induction Chemotherapy
In a Chinese phase III study reported in JAMA Oncology, Dai et al found that induction chemotherapy followed by radiotherapy alone was noninferior in terms of progression-free survival vs induction chemotherapy followed by concomitant chemoradiotherapy in the first-line treatment of locoregionally...
AUA, ASTRO, SUO Release Clinical Practice Guidelines on Salvage Therapy for Prostate Cancer
The American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released new clinical practice guidelines on salvage therapy for patients with prostate cancer. These guidelines were reported on by Morgan...
Online Genetic Education Programs May Spur Testing for Patients at Risk for Cancer
Researchers have demonstrated that an online genetic education program may encourage patients with a family history of cancer to undertake genetic testing, according to a recent study published by Rodriguez et al in Gastroenterology. Background Although research has shown that an inherited...
Christopher A. Barker, MD, on New Data on Vismodegib and Radiotherapy for Basal Cell Carcinoma of the Head and Neck
Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II study results showing that patients with locally advanced, unresectable basal cell carcinoma of the head and neck experienced improved quality of life after induction and concurrent vismodegib with...
Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib
Nabil F. Saba, MD, of Emory University, discusses study findings on 2-year survival rates in patients with recurrent metastatic head and neck squamous cell carcinoma who received pembrolizumab plus cabozantinib. The progression-free survival rate of 32% and the overall survival rate of 55% suggest...
Novel Monotherapy in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
In an analysis reported in the Journal of Clinical Oncology, Arrillaga-Romany et al found that single-agent ONC201 (dordaviprone), a first-in-class imipridone, showed activity in recurrent histone 3 (H3) K27M-mutant diffuse midline glioma. As noted by the investigators, “H3 K27M–mutant diffuse...
President’s Cancer Panel Report Highlights Opportunities to Accelerate Progress Toward the National Cancer Plan
A new report from the President’s Cancer Panel offers recommendations in five priority areas to accelerate progress toward implementing the National Cancer Plan and achieving the Biden-Harris Administration’s Cancer Moonshot goal of ending cancer as we know it. The report, delivered to President...
Risk of Stroke in Survivors of Head and Neck Cancer
In a Singaporean study reported in JAMA Network Open, Yip et al found that survivors of head and neck cancer were at an increased risk of stroke compared with the general population. Study Details The registry-based cross-sectional study involved 9,803 survivors—excluding those with a history of...
Exposure to Secondhand Smoke During Chemotherapy May Decrease Treatment Efficacy in Patients With Head and Neck Cancer
Researchers have found that exposure to secondhand smoke during treatment with cisplatin may reduce its effectiveness in patients with head and neck cancer, even if they don’t have a history of smoking, according to a recent study published by Sadhasivam et al in the International Journal of...
U.S. Individuals With Incarceration History May Have Lower Likelihood of Undergoing Cancer Screenings
Investigators have found that U.S. individuals with a history of incarceration may have worse access to and receipt of breast cancer and colorectal cancer screenings compared with those without a history of incarceration, according to a recent study published by Zhao et al in JAMA Health Forum....
Romidepsin Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of Ro-CHOP Trial
As reported in the Journal of Clinical Oncology by Camus et al, the final analysis of the phase III Ro-CHOP trial showed no significant progression-free or overall survival benefit with the addition of romidepsin (Ro) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously...
Adding First-Line Nivolumab to Chemotherapy in Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
As reported in the Journal of Clinical Oncology by Yelena Y. Janjigian, MD, and colleagues, 3-year follow-up of the phase III CheckMate 649 trial has shown the continued benefit of the addition of nivolumab to chemotherapy in the first-line treatment of advanced gastric, gastroesophageal junction,...
